Insights

With the ever-changing face of biotech, the pace of change within the medicines, diagnostics, devices and vaccines fields is accelerating as we move into 2026.  Some of the changes that are occurring are the result of evolutionary changes – i.e.  faster and cheaper tests and smarter clinical trials – whilst other changes are more revolutionary, involving AI that is being used to design molecules, or gene therapies that can truly cure disease.

This article explores the 10 trends that are expected to shape the global life sciences landscape in 2026 and beyond.  We explore some of the newest innovations, why they matter, and things to take into account if you’re developing products, hiring new staff, investing, or just trying to keep up with all the changes.

1) AI evolving from assistant to the engine of drug design and development

2026 will see AI become a practical, deal-making technology that shortens timelines and drives new partnerships.

Big pharma and nimble biotechs are signing multi-year collaborations to use generative and structure-based models to design antibodies, proteins and small molecules; some companies now claim weeks (not months) from in-silico design to lab-ready candidates.  That’s shifting risk and cost earlier in the pipeline and creating a new ecosystem of AI platform companies, synthetic biology partners and data-sharing consortia.

Why it matters:  faster hypothesis generation + improved candidate quality = fewer expensive late-stage failures and a higher throughput of first-in-class molecules.

What to watch:  regulatory guidance for AI-designed therapeutics, IP disputes around model-generated sequences and the first clear clinical success stories for AI-designed drugs.

2) mRNA goes beyond vaccines — therapeutics and rapid response platforms

mRNA is now a platform category, not just a COVID-era vaccine technology.  Companies and researchers are expanding mRNA applications into oncology vaccines, protein replacement therapies and even in vivo gene editing delivery.  There’s heavy interest in rapid, adaptable vaccine platforms (pandemic preparedness, variant-tuned flu shots) and in commercialising mRNA for chronic or hard-to-treat diseases.  Investment and pipeline activity continue to grow, but so do questions about scalable manufacturing, durability of immune responses for certain indications and public/regulatory acceptance.

Why it matters:  mRNA’s programmability allows rapid iteration and broad applicability — turning what used to be custom biologics into more modular products.

What to watch:  large-scale mRNA manufacturing capacity announcements, phase-2/3 readouts for non-infectious disease indications (e.g., cancer vaccines) and any regulatory policy shifts that affect emergency or accelerated use.

3) Cell & gene therapies move into commercialisation and real-world scalability

After a decade of scientific breakthroughs, 2026 is about translating single-patient miracles into widely available, manufacturable treatments.  Regulators and industry are focused on scalable manufacturing, standardised potency assays, cost-of-goods pressures and payer models (outcomes-based contracts, amortised payments).  That maturation is already driving guidance, roundtables and policy conversations globally as agencies balance speed of access with safety and long-term monitoring.

Why it matters:  cures (or near-cures) for genetic diseases are reaching approval — but delivering them affordably and equitably is the next hard engineering and policy problem.

What to watch:  new commercial supply-chain models (centralised vs decentralised manufacturing), approvals of ex vivo and in vivo therapies beyond rare diseases and progress on reimbursement innovations.

4) Liquid biopsy and multi-omics diagnostics scale toward population screening

Diagnostics are moving from single-analyte tests to multi-omics platforms that combine DNA, RNA, proteins and methylation signals to detect disease earlier and non-invasively.  Multi-cancer early detection and expanded liquid biopsy panels are progressing through trials and pilot screening programs, while integration with AI improves signal detection and reduces false positives.  If these approaches scale, they could shift cancer care from late intervention to earlier, curative treatments.

Why it matters:  earlier detection saves lives and shifts healthcare economics — but population screening also raises questions around follow-up care, overdiagnosis and health equity.

What to watch:  results from large multi-cancer detection trials, reimbursement decisions for population screening and clinical pathways for managing positive screens.

5) Point-of-care (POC) and decentralised testing become smarter and more connected

POC diagnostics — tests done in clinics, pharmacies or at home — are becoming faster, more accurate and integrated with digital care.  Advances in microfluidics, isothermal amplification and on-device analytics let clinicians get actionable results in minutes.  Combine that with smartphone integration and cloud analytics and you have a distributed diagnostic network that can triage patients, guide therapy and feed epidemiologic surveillance.  The trend is stronger in resource-limited settings where decentralised testing can dramatically expand access.

Why it matters:  faster decision-making at the bedside reduces hospital stays and unnecessary referrals; it also democratises access to testing.

What to watch:  regulation and quality-control standards for POC devices, digital health integration for test results and reimbursement models enabling widespread adoption.

6) Diagnostics + therapeutics converge (theranostics and companion diagnostics)

Precision medicine keeps maturing:  diagnostics are no longer separate from treatment but are paired as companions that determine who will benefit from a therapy (and who won’t).  That extends beyond oncology into infectious disease, neurology and rare disease.  Expect more co-development deals between diagnostic firms and pharma and tighter regulatory alignment for simultaneous review of test + drug packages.

Why it matters:  better matching of drugs to patients improves outcomes and reduces wasted therapy spend.

What to watch:  co-approval case studies, payer policies requiring companion tests for coverage and lab preparedness for new companion assays.

7) Medical devices get smarter with embedded software and AI — and face new regulatory attention

Medical devices from wearables to implantables are embedding software, machine learning and connectivity, enabling continuous monitoring and adaptive therapies.  While this offers powerful new capabilities (real-time alerts, closed-loop control, remote titration), it also raises cybersecurity and software-validation questions.  Regulators are increasingly focused on lifecycle management of AI/ML-enabled devices — how models are updated, validated post-market and kept secure.

Why it matters:  the value of devices is increasingly driven by software and data, not just hardware design.

What to watch:  regulators’ rules on AI/ML device updates, recalls or advisories tied to software vulnerabilities and standards for interoperability and data protection.

8) Manufacturing innovation:  onshore, modular and continuous bioprocessing

Supply-chain resilience is a priority.  Expect more onshore and regional biomanufacturing capacity, modular (single-use) clean rooms and adoption of continuous manufacturing for biologics and vaccines to reduce cost and increase surge capacity.  These shifts are driven by geopolitical concerns, lessons from pandemic supply bottlenecks and the commercial pressures of cell/gene and mRNA products that require specialised production.

Why it matters:  reducing lead times and improving scale economics is essential to make advanced therapies commercially viable.

What to watch:  investments in regional manufacturing hubs, approvals of continuous process validation approaches and partnerships between CMOs and biotech innovators.

9) New commercial and reimbursement models for high-cost therapies

As more high-efficacy — and high-price — therapies reach approval, payers and governments are experimenting with outcomes-based contracts, annuity payments and risk-sharing agreements.  These models try to align payment with real-world benefit and spread one-time costs over time or performance.  Expect pilots and broader adoption in 2026, especially for potentially curative gene therapies and cell therapies.

Why it matters:  how therapies are paid for will determine patient access and the sustainability of innovation.

What to watch:  public-private pilots for annuity payments, real-world evidence frameworks that feed payments and policy decisions in major markets (US, EU, UK, Japan) that set precedent.

10) Global regulatory harmonisation — and heated bioethics debates

Rapid scientific progress brings complex ethical and regulatory questions.  From germline editing debates to applications of in-vivo gene editing and human enhancement, public scrutiny and regulatory responses are intensifying.  At the same time, regulators are trying to harmonise accelerated pathways for complex biologics and digital therapeutics so that innovation can cross borders more smoothly.  Recent years have seen global meetings, roundtables and updated guidance as agencies grapple with balancing innovation and patient protection.

Why it matters:  policy decisions (and public sentiment) shape what therapies reach patients and how quickly.

What to watch:  international regulator summits, high-profile ethical decisions or moratoria and the first major policy changes that affect cross-border clinical trials or approvals.

Cross-cutting themes:  equity, data governance and workforce needs

Across all ten trends, three themes recur:

• Health equity & access:  new technologies risk widening gaps unless deployment plans explicitly include LMICs and underserved populations.  Diagnostics and decentralised care offer solutions — but only with funding and policy commitments.
• Data governance:  AI and multi-omics depend on massive, diverse datasets.  Who owns data, how consent is obtained and how biases are addressed will determine both scientific validity and public trust.
• Workforce evolution:  biotech needs new hybrids — people who combine biology, data science, regulatory know-how and manufacturing engineering.  Hiring and training will be a major bottleneck unless companies invest in upskilling.

Recommendations — how to prepare in 2026

For biotech founders and execs:

• Prioritise partnerships:  combine domain expertise with AI/platform partners rather than trying to build everything in house.
• Build manufacturability into early programs:  scalable processes sell better to investors and payers.
• Start payer conversations early for high-cost assets — model different reimbursement scenarios.

For investors:

• Look for companies that can demonstrate robust datasets, regulatory path clarity and manufacturing plans.
• Watch platform plays (AI, mRNA delivery, modular manufacturing) that can multiply returns across multiple programs.

For clinicians and hospitals:

• Pilot point-of-care and telehealth workflows now so you can integrate new diagnostics and remote monitoring with minimal friction.
• Invest in education for interpreting multi-omics and AI outputs.

For policy makers:

• Support public data infrastructure, advance harmonised regulatory frameworks and design reimbursement pilots that protect patients while enabling access to high-value therapies.

Final note — cautious optimism

The biotech field entering 2026 is both exhilarating and sobering.  The science — from AI-designed molecules to curative gene therapies and multi-cancer liquid biopsies — is closer than ever to altering care for millions.  But the non-scientific hurdles (manufacturing scale, equitable access, regulatory frameworks and ethical guardrails) remain large and real.  Expect 2026 to be a year of tangible wins and difficult policy conversations — and an inflection point where technologies mature from proofs-of-concept into systems that can be delivered reliably and ethically at scale.